ImmuCell Corporation (NASDAQ:ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its first quarter ended March 31, 2014. For the first quarter ended March 31, 2014, ImmuCell Corporation (NASDAQ:ICCC) reported a product sales increase of 13% to $2.08 million versus $1.85 million in the comparable period of the prior year. The Company has now achieved positive sales growth for seven consecutive quarters and for thirteen out of the last fourteen quarters. ImmuCell Corporation (NASDAQ:ICCC) stock performance was 12.86% in last session and finished the day at $3.95. Traded volume was 19,477.00million shares in the last session and the average volume of the stock remained 2.46K shares. The beta of the stock remained -0.17. ImmuCell Corporation (NASDAQ:ICCC) insider ownership is 9.00%.

TG Therapeutics, Inc (NASDAQ:TGTX) released its earnings data on Monday. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.19) by $0.06, Analyst Ratings.Net reports. TG Therapeutics, Inc. (NASDAQ:TGTX) rose 12.64 percent to $5.08 Thursday on volume of 221,275.00million shares. The intra-day range of the stock was $4.50 to $5.15. TG Therapeutics, Inc. (NASDAQ:TGTX) has a market capitalization of $169.68million.

Relypsa Inc (NASDAQ:RLYP)’s share price was up 5.4% during trading on Tuesday after Wedbush raised their price target on the stock from $56.00 to $57.00, Analyst Ratings News reports. Wedbush currently has an outperform rating on the stock. Relypsa Inc (NASDAQ:RLYP)traded as high as $22.81 and last traded at $22.55, with a volume of 117,607 shares changing hands. The stock had previously closed at $21.39. Relypsa Inc (NASDAQ:RLYP)’s stock on May 15, 2014 reported a increase of 5.68% to the closing price of $23.24. Its fifty two weeks range is $11.55 -$52.74. The total market capitalization recorded $786.57million. The overall volume in the last trading session was 258,835.00million shares. In its share capital, RLYP has 33.85million outstanding shares.

Ohr Pharmaceutical Inc (NASDAQ:OHRP) has announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing squalamine eye drops in patients with diabetic macular edema (DME). Ohr Pharmaceutical CEO Dr Irach B. Taraporewala noted that the company is excited to be working with such a prestigious group of retina specialists in this important early study. On Thursday, shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) advanced 9.74% to close the day at $8.90. Company monthly performance is recorded as -7.20%. OHR Pharmaceutical Inc (NASDAQ:OHRP) quarterly revenue growth is -45.86%.